Document:

MUTUAL RELEASE AND SETTLEMENT AGREEMENT

I.    PARTIES

      This Mutual Release and Settlement Agreement  ("Agreement") is made by and
between PARKER MILLS & PATEL LLP, ("PMP") and VERTICAL  COMPUTER  SYSTEMS,  INC.
"VERTICAL"). The effective date of this Agreement is October 19, 2005

II.   RECITALS

      A. On or about  January 21,  2005,  PMP filed a lawsuit in the Los Angeles
County Superior Court,  entitled Parker Mills & Patel LLP vs. Vertical  Computer
Systems,  Inc. Case No.  BC327609 (the  "Action").  PMP alleged causes of action
for: (1) Breach of Written  Contract;  (2) Account Stated;  (3) Reasonable Value
for Services Rendered; and (4) Breach of Promissory Note.

      B. On April 20, 2005,  VERTICAL  answered  PMP'S  Complaint in the Action,
denying any liability and disputing its obligation to pay the amounts alleged.

      C. It is now the desire of PMP and  VERTICAL to fully and finally  resolve
and settle their differences and disputes pertaining to the Action.

III.  TERMS AND CONDITIONS

      NOW,  THEREFORE,  in consideration of the promises and covenants contained
herein, it is agreed by and between the parties as follows:

      A.  CONSIDERATION.  VERTICAL  agrees  execute  and  deliver to PMP a fully
executed  Promissory  Note ("Note") in the form attached  hereto as Exhibit "A."
Concurrently  with  VERTICAL'S  delivery to PMP of the fully  executed Note, PMP
will deliver to VERTICAL a fully executed Request for Dismissal, with prejudice,
of the Action.

      C. MUTUAL GENERAL RELEASE.

      For  valuable  consideration  stated  herein and above,  the  receipt  and
adequacy of which are hereby acknowledged,  the parties hereto agree to mutually
release  one another  with  respect to the Action,  as set forth  herein  below;
PROVIDED  HOWEVER,  that no  provision  of this Mutual  Release  and  Settlement
Agreement  shall,  or be otherwise  interpreted  to, extend to the terms of this
Agreement and/or of the Note.

            (1) Plaintiff PMP, on behalf itself, its agents, employees, partners
      and attorneys of record in the Action hereby fully and forever,  generally
      and  specifically,  releases and discharges  VERTICAL,  and its respective
      past and present agents, employees, officers, directors,  shareholders and
      attorneys (the  "Vertical  Releasees")  from any and all claims,  demands,
      actions, rights, causes of action, obligations, liens, damages, judgments,
      indemnities, subrogations, duties, controversies or any liability or claim
      of any  nature,  character  or  description,  whether at law or in equity,
      whether or not now known,  suspected or claimed,  that PMP has ever had or
      now have or might in the future have,  against the  Vertical  Releasees by
      reason of any act, failure to act, cause,  matter or event arising out of,
      or in any way  relating  to the  subject  matter of  and/or  the facts and
      transactions  alleged in the Action or any and all other damages or injury
      of any nature whatsoever,  past, present and future, in any way related to
      the Action;

                     MUTUAL RELEASE AND SETTLEMENT AGREEMENT
                                 PMP v. Vertical
                                   - 1 of 7 -
<PAGE>

            (2) The Vertical Releasees,  hereby fully and forever, generally and
      specifically,  release  and  discharge  PMP and its  respective  past  and
      present agents, employees, partners, and attorneys of record in the Action
      (the "PMP Releasees") from any and all claims, demands,  actions,  rights,
      causes of action,  obligations,  liens, damages,  judgments,  indemnities,
      duties,  controversies or any liability or claim of any nature,  character
      or  description,  whether at law or in  equity,  whether or not now known,
      suspected  or  claimed,  that  have  ever  had or now have or might in the
      future have,  against the PMP  Releasees by reason of any act,  failure to
      act, cause,  matter or event arising out of, or in any way relating to the
      subject matter of and/or the facts and transactions  alleged in the Action
      or any and all other  damages  or injury of any nature  whatsoever,  past,
      present and future, in any way related to the Action.

      D.  WAIVER OF  CALIFORNIA  CIVIL  CODE  SECTION  1542.  Each  Party  fully
understands  that he, she or it may have  additional  unknown claims or may have
suffered injuries or damages that are presently unknown to them, which arise out
of or relate to the Action and that unknown  complications  of  presently  known
injuries  may  arise,  develop  or be  discovered  in the  future.  The  Parties
acknowledge,  however,  that this Mutual Release and  Settlement  Agreement is a
full and final release of all unknown and  unanticipated  injuries,  damages and
claims  arising out of or pertaining  to the Action as relates to them,  and the
matters released in this Agreement,  as well as to those now known or disclosed,
and all parties  hereto waive all rights or benefits  which they now have, or in
the future may have,  under the terms of Section  1542 of the  California  Civil
Code, with regard to the Action and the matters released in this Agreement.

      California Civil Code, Section 1542, reads as follows:

             A GENERAL  RELEASE DOES NOT EXTEND TO THE CLAIMS WHICH THE CREDITOR
             DOES NOT KNOW OR  SUSPECT  TO EXIST IN HIS OR HER FAVOR AT THE TIME
             OF EXECUTING  THE  RELEASE,  WHICH IF KNOWN BY HIM OR HER MUST HAVE
             MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

                     MUTUAL RELEASE AND SETTLEMENT AGREEMENT
                                 PMP v. Vertical
                                   - 2 of 7 -
<PAGE>

      E. WAIVER OF MISTAKE OF FACT OR LAW. In entering into this Agreement,  the
Parties  assume  the  risk of any  mistake.  If any  party  should  subsequently
discover that any fact relied upon in entering  into this  Agreement was untrue,
or that their understanding of the facts or of the law was incorrect, that party
shall not be entitled to any relief in connection therewith,  including, without
limitation,  on the generality of the  foregoing,  any alleged right or claim to
set aside or rescind  this  Agreement.  This  Agreement is intended to be and is
final and binding upon each of the Parties  regardless of any mistake of fact or
law or any other circumstance whatsoever.

      F.  REPRESENTATIONS  AND  WARRANTIES  BY ALL PARTIES  HERETO.  All Parties
represent and warrant that: (1) They are authorized to compromise and settle all
of the claims which are the subject of this  Agreement;  (2) They have not sold,
transferred,  conveyed,  signed,  hypothecated,  or  otherwise  disposed  of any
claims, rights,  demands,  actions and causes of action which are the subject of
the  Action,  or the  Agreement;  and (3) They  agree  to  indemnify  the  other
releasing  parties and hold them harmless  against any future claims  brought by
anyone claiming an interest in the Action, including any lien claimant.

      G. ENTIRE AGREEMENT. This Agreement contains the sole, complete and entire
understanding of the Parties and may not be altered, modified, or changed in any
manner  except  by a writing  duly  executed  by said  parties.  No  statements,
promises or representations  have been made by any settling party to another, or
relied upon, and no consideration has been, or is, offered,  promised,  expected
or held out, other than as stated in this Agreement.  No party is relying on any
representations  other than those expressly set forth herein.  There are no oral
or written collateral  agreements other than the Note. All prior discussions and
negotiations  have been and are, merged and integrated  into, and superseded by,
this Agreement.

      H. FEES AND COSTS. Each party shall bear its own costs and attorneys' fees
related to the Action and any matters released  herein.  If any action at law or
in equity,  including an action for declaratory relief, is brought to enforce or
interpret  the  provisions  of this  Agreement,  the  prevailing  party shall be
entitled to  reasonable  costs and  attorneys'  fees in  bringing,  prosecuting,
and/or defending such action.

      I. SUCCESSORS AND ASSIGNS.  This Agreement shall be binding upon and inure
to the  benefit  of the  parties  and their  respective,  successors,  devisees,
executors, affiliates, representatives,  assigns, officers, directors, partners,
agents and employees.

      J.  CALIFORNIA  LAW. This  Agreement is executed and delivered  within the
State of California,  and the rights and obligations of Parties  hereunder shall
be governed by, and construed and enforced in accordance  with,  the laws of the
State of California.

      K.  JURISDICTION/VENUE.  This Agreement and any claim related  directly or
indirectly to this Agreement  shall be governed and construed in accordance with
the laws of the State of California  (without  giving regard to the conflicts of
law  provisions  thereof).  No such  claim  shall be  commenced,  prosecuted  or
continued  in any forum other than the federal and state  courts of the State of
California located in the County of Los Angeles,  and each of the Parties hereby
submits to the  jurisdiction  of such courts.  Each of the Parties hereto hereby
waives any and all rights to argue that this choice of forum provision is or has
become unreasonable in any legal proceeding.

                     MUTUAL RELEASE AND SETTLEMENT AGREEMENT
                                 PMP v. Vertical
                                   - 3 of 7 -
<PAGE>

      L.  JOINT  PRODUCT.  This  Agreement  is  the  product  of  bargained  for
arms-length  negotiations  between the Parties,  by and through their respective
counsel.  This  Agreement  is the joint  product of all of the Parties and their
respective counsel and, therefore, any construction of the intent of the parties
hereto or  language  hereof to be made by a court of law shall not be  construed
individually against any Party hereto.

      M. GOOD FAITH. The Parties agree that this Agreement is being entered into
in good faith and without fraud, coercion, duress, or undue influence.

      N.  NON-ADMISSION  OF  LIABILITY.  The Parties agree that the execution of
this  Agreement  is a  compromise  and  settlement  of  disputed  claims  and/or
potential  disputed claims,  and that the furnishing of consideration  under the
terms of this  Agreement  shall  not be  deemed or  construed  as an  admission,
evidence or indication,  in any degree,  of liability or  responsibility  by the
parties herein at any time for any purpose.  It is further agreed and understood
that this  Agreement  is being  entered  into solely for the purpose of avoiding
further expense and inconvenience  from further litigation of any and all of the
claims in the Action,  or any claims related to such,  whether  asserted or not,
and may not be  referred  to in this or any  other  litigation,  whether  or not
arising  from the same  facts and  transactions  of the  Action,  except for the
purpose of enforcing the terms of this Agreement.

      O. LEGAL CAPACITY.  The  undersigned  represent and warrant that they have
the right,  power,  legal capacity,  and authority to enter into and perform the
obligations  under this Agreement on their own behalf and on behalf of anyone or
any entity they represent and that no further  approval or consent of any person
or  entity is  necessary  for them to enter  into and  perform  the  obligations
contained in this Agreement.

      P. NECESSARY ACTS. The  undersigned  represent and warrant that they shall
do all acts and  execute  and deliver all  documents  necessary,  convenient  or
desirable to effect all provisions of this Agreement.

      Q.  EXECUTION IN  COUNTERPARTS.  This  Agreement may be executed in two or
more  counterparts,  each  counterpart  being  executed  by less than all of the
Parties hereto,  and shall be equally effective as if a single original had been
signed by all Parties; but all such counterparts shall be deemed to constitute a
single Agreement, and this Agreement shall not be or become effective unless and
until each of the  signatory  Parties  below shall have signed at least one such
counterpart  and caused the  counterpart  so executed to be delivered to counsel
for the  adverse  Party.  Facsimile  signatures  are as  effective  as  original
signatures for all purposes.

      R. TIME IS OF THE ESSENCE. The undersigned  understand and agree that time
is of the essence with regard to the provisions of this Agreement.

                     MUTUAL RELEASE AND SETTLEMENT AGREEMENT
                                 PMP v. Vertical
                                   - 4 of 7 -
<PAGE>

      S. ACKNOWLEDGMENT.  The undersigned certify and hereby represent that each
is duly  authorized  to  execute  this  Agreement,  and  that  each  has had the
opportunity  to review or has reviewed and read this  Agreement,  including  the
code  section  referred to herein,  with an attorney of their  choice and hereby
warrants that each of the undersigned fully understands the contents,  terms and
conditions of this  agreement and executes it freely and  voluntarily.  Further,
Vertical  acknowledges  that it has consulted with its own  independent  counsel
regarding the terms and  conditions  of this  Agreement,  and the  provisions of
California Rule of Professional Responsibility Section 3-300.

DATED:  October 19, 2005                PARKER MILLS & PATEL LLP

                                        By   /s/ Danny T. Morin
                                        ----------------------------------------

                                        ----------------------------------------
                                             DANNY T. MORIN, Partner

DATED:  October____, 2005               VERTICAL COMPUTER SYSTEMS, INC.

                                        By:   /s/ Richard Wade
                                        ----------------------------------------

                                        ----------------------------------------
                                              RICHARD WADE, President & CEO

Approved as to form and content:

DATED:   October 19, 2005               DATED:   October 18, 2005

     PARKER MILLS & PATEL LLP                LAW OFFICES OF CHAD BIGGINS

By:   /s/ Danny T. Morin                      /s/ Chad Biggins
   ---------------------------------       ----------------------------------
          DANNY T. MORIN                    CHAD BIGGINS, ESQ.
                                        Attorneys for Vertical Computer
                                        Systems, Inc.

                     MUTUAL RELEASE AND SETTLEMENT AGREEMENT
                                 PMP v. Vertical
                                   - 5 of 7 -
<PAGE>

                                   EXHIBIT "A"
                                   -----------

                                 PROMISSORY NOTE
                                 ---------------

      FOR VALUE RECEIVED,  the undersigned,  VERTICAL COMPUTER SYSTEMS,  INC., a
Delaware corporation (Borrower),  promises to pay to PARKER MILLS & PATEL LLP, a
California  limited  liability  partnership  (Lender),  the sum of  SEVENTY-FIVE
THOUSAND  Dollars  ($75,000),  with  interest  thereon  at the  rate of six (6%)
percent per annum, payable as follows:

      1. Payment of Principal and Interest. Principal and interest shall be paid
as follows:

            a. All principal then outstanding,  and all interest, fees, charges,
and other  amounts  owing  hereunder and then unpaid shall be due and payable on
January 31, 2008,  (the "Maturity  Date").  Vertical shall pay the Note in equal
monthly installments of $ 3,125.00,  beginning February 1, 2006, for a period of
24 months. Any unpaid principal balance, and any accrued interest and penalties,
shall immediately come due and payable to Lender at the Maturity Date.

            b.  Borrower  shall  pay  all  amounts  owing  under  this  Note  in
immediately  available funds to Lender at Lender's  address as set forth herein,
or at such other place as may be specified in writing by Lender.  Each  payment,
when made,  shall be credited first to interest then due, and then at the option
of Lender to principal,  late charges,  and other fees and expenses  outstanding
hereunder in such order as Lender may determine.

            c.  Payments  received  after 1:00 p.m. on any banking day or at any
time on any Saturday,  Sunday,  or holiday shall be deemed  received on the next
banking day.

      2. The unpaid principal and accrued interest,  and penalties,  if any, may
be  prepaid  in whole or in part at any time  without  any  prepayment  penalty.
Borrower  agrees  to pay  all  costs  and  expenses,  including  all  reasonable
attorneys'  fees,  for the  collection of this Note upon  default.  All payments
shall be made to Lender at 865 S. Figueroa  Street,  Suite 3200 Los Angeles,  CA
90017,  or at such other  place as Lender or any holder  hereof may from time to
time designate in writing.

      3. In addition, payments not received by Lender by the tenth (10th) day of
the month are subject to a late charge of five (5%) of said payment.

      4. This Note shall,  at the option of the Lender or any holder hereof,  be
immediately  due and payable upon  failure to make any payment due  hereunder or
for breach of any condition of any security interest, mortgage, pledge agreement
or  guaranty  granted  as  collateral  security  for this  Note or breach of any
condition of any security agreement or mortgage,  if any, having a priority over
any security agreement or mortgage on collateral  granted,  in whole or in part,
as  collateral  security  for this  Note or upon the  filing by  Borrower  of an
assignment  for the benefit of  creditors,  bankruptcy,  or for relief under any
provisions of Title 11 of the United States Code; or by suffering an involuntary
petition in bankruptcy or receivership not vacated within thirty days.

                     MUTUAL RELEASE AND SETTLEMENT AGREEMENT
                                 PMP v. Vertical
                                   - 6 of 7 -
<PAGE>

      5. In the event this Note shall be in default, and placed with an attorney
for  collection,  then Borrower  agrees to pay all reasonable  attorney fees and
costs of collection.

      6. If any action at law or in equity,  including an action for declaratory
relief,  is brought to enforce or interpret  the  provisions  of this Note,  the
prevailing  party shall be entitled to reasonable  costs and attorneys'  fees in
bringing, prosecuting, and/or defending such action.

      7.  This  Note  shall be  binding  upon and  inure to the  benefit  of the
Borrower and Lender alike, including their respective successors and assigns.

      8. This Note and any claim  related  directly or  indirectly  to this Note
shall be governed  and  construed  in  accordance  with the laws of the State of
California  (without giving regard to the conflicts of law provisions  thereof).
No such claim shall be  commenced,  prosecuted  or  continued in any forum other
than the  federal  and state  courts of the State of  California  located in the
County of Los Angeles,  and Borrower hereby submits to the  jurisdiction of such
courts.  Borrower  hereby waives any and all rights to argue that this choice of
forum provision is or has become unreasonable in any legal proceeding.

      9. The Borrower and all other  parties to this Note,  whether as endorsers
or sureties, waives demand,  presentment and protest and all notices thereto and
further  agree to remain bound,  notwithstanding  any  extension,  modification,
waiver,  or other  indulgence by any holder or upon the discharge or relea se of
any obligor  hereunder or to this Note, or upon the exchange,  substitution,  or
release of any collateral granted as security for this Note.

      10. The Borrower and each endorser of this Note waives presentment, notice
and protest, all suretyship defenses and agrees to all extensions,  renewals, or
releases, discharge or exchange of any other party or collateral without notice.

      11. This Note shall not be modified,  amended,  or  terminated,  except by
written agreement duly executed and delivered by both Lender and Borrower.

DATED:  October____, 2005

                                       VERTICAL COMPUTER SERVICES, INC.

                                       By:   /s/ Richard Wade
                                           -------------------------------------
                                             Richard Wade, its President and CEO

                     MUTUAL RELEASE AND SETTLEMENT AGREEMENT
                                 PMP v. Vertical
                                   - 7 of 7 -February
      8, 2006

    

    Joe
      J.
      Dervan, Ph.D

    Head
      of
      Protein Chemistry

    Protalex,
      Inc.

    145
      Union
      Square Drive

    New
      Hope,
      PA 18938

    

    Telephone:
      215.862.9720

    Fax:
      215.
      862.6614

    Email:
      jdervan@protalex.com

    

    Revision
      History:

    

    PREX7000B:
      The payment schedule was revised and the state changed to Delaware in Appendix
      III, General Terms and Conditions, section o.

    

    PREX7000A:
      The placebo batch and placebo stability program were removed. An additional
      analytical method (RP-HPLC) will be evaluated and utilized to evaluate samples
      for this project, and a two-week time point was added to section IIC in
      PREX7000A.

    

    PREX7000B:
      This
      service estimate is executable if signed and returned within 30
      days.

    

    
      	
              Service
                Estimate

            
	
              Limited
                Formulation Development and Manufacture of One Lyophilized Batch
                of

            
	
              PRTX-100
                for Phase II Clinical Use

            

    

     

    Objective:

    

    Protalex,
      Inc. (“Protalex”) has requested that AAIPharma Inc. (“AAI”) evaluate whether
      PRTX-100 can be manufactured as a lyophilized formulation [*****]1  versus
      the current liquid formulation. AAI will perform limited formulation development
      and manufacture one (1) lyophilized batch of PRTX-100 based on the results
      of
      the proposed formulation development study. AAI’s Safety Department has assigned
      a level 2 safety rating for the active pharmaceutical ingredient [*****].
      

    

    Summation
      of Services:

    
      	 	 
	
              Evaluation
                of Analytical Methods 

            	 
	
              Limited
                Formulation Development

            	 
	
              Manufacture
                of Engineering Batch

            	 
	
              Manufacture
                of Clinical Batch of PRTX-100

            	 
	
              Clinical
                Batch Stability 

            	 
	
              Project
                Management

            	 
	
              Total
                Estimated Cost 

            	
              $[*****]*

            

    

    *Excludes
      materials and specialty items.

     

      
        

      

    

    1
      [*****]
      denotes sections of the document which have been redacted in connection with
      a
      request for confidential treatment.

    
 

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    THE
      TERMS
      AND PROVISIONS OF THE FOLLOWING ATTACHED APPENDICIES ARE INCORPORATED HEREIN
      BY
      REFERENCE AND SHALL BE BINDING ON THE PARTIES:

    

    
      	
              APPENDIX
                I

            	
              DESCRIPTION
                OF SERVICES

            
	
              APPENDIX
                II

            	
              PAYMENT
                SCHEDULE AND TERMS

            
	
              APPENDIX
                III

            	
              GENERAL
                TERMS AND CONDITIONS

            

    

    

    THE
      SERVICES DESCRIBED IN THIS SERVICE ESTIMATE, INCLUDING THE APPENDICES HERETO,
      SHALL BE REFERRED TO HEREIN AS THE "SERVICES."

    

    THE
      PHARMACEUTICAL PRODUCT TO BE MANUFACTURED PURSUANT TO THIS SERVICE ESTIMATE
      SHALL BE REFERRED TO HEREIN AS THE "PRODUCT." 

    

    THIS
      SERVICE ESTIMATE SHALL BECOME BINDING ON THE PARTIES IF SIGNED BY AN AUTHORIZED
      REPRESENTATIVE OF PROTALEX,
      INC.
      AND
      RETURNED TO AAI WITHIN 30 DAYS OF THE DATE HEREOF.

    

    
      	
              AAIPharma
                Inc.

            	
              Protalex,
                Inc.

            
	 	 
	
              __________________________________

            	
              __________________________________

            
	
              Reviewed
                and Approved by:

            	
              Printed
                Name of Authorized Representative

            
	
              Beth
                Balkcum

            	 
	
              Manager,
                Product Development

            	 
	
              Project
                Management

            	 
	 	 
	 	 
	
              ______________________

            	
              ___________________________

            
	
              Date

            	
              Signature

            
	 	 
	 	
              ______________________

            
	
              __________________________________

            	
              Date

            
	
              Reviewed
                and Approved by:

            	 
	
              Ludo
                Reynders, Ph.D.

            	
              ________________________

            
	
              President
                and CEO

            	
              Purchase
                Order Number

            

    

    

    Please
      return signed document to:

    Cynthia
      Pawlik, Ph.D.

    Project
      Manager

    
      	
              AAIPharma
                Inc.

            	
              Telephone:
                843.746.2526

            
	
              4221
                Faber Place Drive

            	
              Facsimile:
                843.746.2550

            
	
              Charleston,
                SC 29405

            	
              E-mail:
                cynthia.pawlik@aaipharma.com

            

    

    

    
      
        
        

      

      
        Page
          2 of 12

        
          

        

      

      
        
        

      

    

    

    Appendix
      I

    Description
      of Services

    

    
      	I.	
              Project
                Responsibility

            

    

    

    
      	 	
              A.

            	
              Protalex
                will supply AAI with Active Pharmaceutical Ingredient (“API”) and a
                current Material Safety Data Sheet (“MSDS”). Note:
                Protalex will supply the API accompanied by a Certificate of Analysis
                (“COA”) and a release statement or a COA from an independent laboratory
                in
                order for AAI to perform limited release testing.
                

            

    

    

    
      	
            	B.	
              AAI
                will source sufficient amounts of excipients, packaging components,
                materials, and dedicated equipment on behalf of Protalex for use
                in the
                activities described herein. The costs will be passed-through to
                Protalex
                plus 15% for sourcing and handling.

            

    

    

    
      	 	
              C.

            	
              AAI
                will perform full COA testing per USP or specification for all raw
                materials and packaging components.

            

    

    

    
      	 	
              D.

            	
              AAI
                will provide all necessary COA’s and executed batch records to Protalex
                for final release.

            

    

    

    
      	II.	
              Evaluation
                of Methods and Manufacture of Experimental Batch
                

            

    

    

    
      	 	
              A.

            	
              Evaluation
                of Analytical Methods

            

    

     

    AAI
      will 

    
      	
            	·	
              Review
                the current methods provided by
                Protalex.

            

    

    
      	 	
              ·

            	
              Evaluate
                the following methods to ensure the methods are operating properly
                for the
                analysis of drug product and stability samples in the AAI
                facility:

            

    

    
      	 	
              o

            	
              Concentration
                by mBCA
                

            

    

    
      	 	
              o

            	
              Concentration
                by UV 2801

            

    

    
      	 	
              o

            	
              RP-HPLC
                

            

    

    
      	 	
              o

            	
              SDS-PAGE
                (assume non-reducing conditions and Coomassie Stain)1

            

    

    
      	 	
              o

            	
              SEC
                (Size Exclusion Chromatography)

            

    

    
      	 	
              o

            	
              IEF
                (isoelectric focusing)

            

    

    
      	 	
              o

            	
              PX1
                binding affinity using ELISA

            

    

    
      	 	
              ·

            	
              Method
                evaluation will consist of the analysis of three (3) preparations
                of a
                single lot or one (1) preparation of each of three (3) lots of material.
                AAI will compare data to the COA provided with the material or, if
                COA
                data are not available, will provide data to Protalex for review
                to
                confirm success of evaluation
                studies.

            

    

    
      	 	
              ·

            	
              Issue
                a report for the methods evaluated including tabulated results and
                example
                chromatography.

            

    

    

    Note:
      1The
      UV
      280 and SDS-PAGE methods will be evaluated as release tests for the API.

     

    
      
        
        

      

      
        Page
          3 of 12

        
          

        

      

      
        
        

      

    

    The
      estimated cost for evaluation of the analytical methods may increase after
      AAI
      reviews the methods provided by Protalex. 

    

    B. Development
      and Validation of Cleaning Verification Test Method   

    

    AAI
      will

    
      	
            	·	
              Optimize
                an assay method for testing trace levels of active residues and then
                establish the performance and suitability of the
                method.

            

    

    
      	
            	·	
              Validate
                the method for testing trace levels of active
                residues.

            

    

    
      	
            	·	
              Collect
                samples from product contact surfaces for major equipment and test
                for
                trace levels of active residues.

            

    

    
      	
            	·	
              Issue
                a final method and report to Protalex. 

            

    

    

    C.
      Limited Formulation Development 

    

    AAI
      will:

    
      	
            	·	
              Prepare
                a protocol to be approved by Protalex.

            

    

    
      	
            	·	
              Prepare
                and lyophilize in the FDL lyophilizer (Wilmington, NC) four (4) prototype
                batches using a conservative lyo
                cycle.

            

    

    
      	
            	·	
              Prepare
                samples for product contact study and filtration loss study to be
                evaluated for purity (RP-HPLC) and stability (SEC and
                SDS-PAGE).

            

    

    
      	
            	·	
              Place
                and store four (4) prototypes on stability at the following
                conditions:

            

    

    

    
      	
              TESTS
                PERFORMED

            
	
              1. Appearance

            
	
              2. pH

            
	
              3. RP-HPLC

            
	
              4. SEC

            
	
              5. SDS-PAGE

            
	
              6. Completeness,
                clarity and color of solution after reconstitution and reconstitution
                time

            
	
              7. Moisture
                (cKF)

            

    

    

    SAMPLING
      SCHEDULE 

    
      	
              Time
                (Months)

            	
              2-8°C

            	
              25°C/60%
                RH

            	
              40°C/75%
                RH

            
	
              0

            	
              Tests
                1-7

            
	
              0.5

            	
              HOLD*

            	
              Tests
                1-7

            	
              Tests
                1-7

            
	
              1

            	
              HOLD*

            	
              Tests
                1-7

            	
              Tests
                1-7

            
	
              2

            	
              HOLD*

            	
              Tests
                1-7

            	
              Tests
                1-7

            
	
              3

            	
              Tests
                1-7

            	
              Tests
                1-7

            	
              Tests
                1-7

            

    

    

    *Samples
      will only be tested if significant change occurs during the 3 months storage
      at
      25°C/60%
      RH,
      or if requested by Protalex, at an additional cost.

    

    
      
        
        

      

      
        Page
          4 of 12

        
          

        

      

      
        
        

      

    

    
      	
            	·	
              Prepare
                a technical transfer document summarizing study results. The new
                formulation will be used in the engineering and clinical
                batch.

            

    

    

    D.
      Development and Validation of Microbiological Test Methods

    

    AAI
      will:

    
      	
            	·	
              Evaluate
                the suitability of the USP sterility test method (membrane filtration)
                and
                validate the method by performing appropriate bacteriostasis/fungistasis
                testing on a single batch (ref. USP
<71>)

            

    

    
      	
            	·	
              Evaluate
                the suitability of the USP LAL test method and validate the method
                by
                performing appropriate inhibition and dilution studies on a single
                batch
                (ref. USP <85>)

            

    

    

    
      	 	
              E.

            	
              Process
                Transfer and Engineering Batch

            

    

     

    AAI
      will

    
      	 	
              ·

            	
              Review
                all technical documentation provided by Protalex.

            

    

    
      	 	
              ·

            	
              Generate
                appropriate test procedures and specifications for manufacturing
                PRTX-100.

            

    

    
      	 	
              ·

            	
              Prepare
                and issue a batch record to manufacture one (1) engineering batch
                of
                PRTX-100.

            

    

    
      	 	
              ·

            	
              Set-up
                AAI equipment as appropriate for the Protalex-specified packaging
                components and perform trial runs to optimize the operating parameters
                of
                the filling equipment (Note: If AAI does not purchase the components
                directly, then Protalex will be responsible for sourcing the components
                in
                packaging configurations suitable for AAI gross cleaning
                equipment).

            

    

    
      	 	
              ·

            	
              Compound,
                aseptically fill and lyophilize one full-scale engineering (test)
                batch as
                outlined in the batch record; if API is limited, AAI will use surrogate
                material or placebo to fill the shelves of the AAI-Charleston
                lyophilizer.

            

    

    
      	 	
              ·

            	
              Perform
                appropriate in-process testing (pH, appearance, fill weight and
                concentration via UV 280).

            

    

    
      	 	
              ·

            	
              Release
                the batch according to specifications agreed upon in writing by Protalex
                and AAI. AAI will test the batch for concentration by UV280, appearance,
                pH, volume in container, isoelectric focusing (IEF), SDS-PAGE, RP-HPLC,
                Size Exclusion Chromatography (SEC), PX1 Binding Affinity (ELISA),
                concentration by mBCA,
                moisture (cKF), completeness, clarity, and color of solution after
                reconstitution, reconstitution time, analytical content (the appropriate
                method is to be determined), particulate matter (via HIAC), endotoxin
                and
                sterility (membrane filtration). 

            

    

    
      	 	
              ·

            	
              Perform
                cleaning verification testing.

            

    

     

    
      
        
        

      

      
        Page
          5 of 12

        
          

        

      

      
        
        

      

    

    
      	 	
              ·

            	
              Ship
                the batch, FOB AAI’s dock, to Protalex or a designated site, as a single
                shipment. Each additional shipment will incur an additional $[*****]
                handling fee. 

            

    

    
      	 	
              ·

            	
              Complete
                the batch record and issue to Protalex.

            

    

    

    Note:
      Protalex intends to use the drug product manufactured in the engineering batch
      in an animal toxicology study. Protalex has requested that AAI ship
      the finished product to a designated site under quarantine while release
      testing is conducted. AAI will provide appropriate documentation of final
      release following completion of required release testing and acceptable
      results.

    

    

    
      	
              Estimated
                Cost

            	
              $[*****]

            

    

    

    

    
      	 	
              III.

            	
              Clinical
                Batch Manufacture 

            

    

    

      AAI
      will

    
      	 	
              ·

            	
              Prepare
                the master batch record - to be approved by
                Protalex.

            

    

    
      	 	
              ·

            	
              Perform
                release testing of API and packaging components based on a COA and
                appropriate testing.

            

    

    
      	 	
              ·

            	
              Perform
                full release testing of excipients based on a COA and appropriate
                testing.

            

    

    
      	 	
              ·

            	
              Evaluate
                the USP bioburden method and validate the method by performing appropriate
                growth promotion studies on a single
                batch.

            

    

    
      	 	
              ·

            	
              Compound,
                aseptically fill, and lyophilize one batch in of PRTX-100 in 3-mL
                vials,
                13 mm finish (Batch size is approximately 1,000
                vials).

            

    

    
      	 	
              ·

            	
              Perform
                appropriate in-process testing during manufacturing (appearance,
                pH,
                bioburden, fill weight and UV280).

            

    

    
      	 	
              ·

            	
              Release
                the batch according to specifications agreed upon in writing by Protalex
                and AAI. AAI will test the active batch for concentration by, appearance,
                UV280, pH, volume in container, IEF, SDS-PAGE, SEC, RP-HPLC, PX1
                Binding
                Affinity (ELISA), concentration by mBCA,
                moisture (cKF), completeness, clarity, and color of solution after
                reconstitution, reconstitution time, analytical content (the appropriate
                method is to be determined), particulate matter (via HIAC), endotoxin
                and
                sterility (membrane filtration). 

            

    

    
      	 	
              ·

            	
              Perform
                cleaning verification testing.

            

    

    
      	 	
              ·

            	
              Inspect,
                label1
                and bulk package the vials - 100% visual inspection; Protalex to
                approve
                label copy in writing or provide finished labels with an approved
                proof
                copy.

            

    

    
      	 	
              ·

            	
              Ship
                the batch, FOB AAI’s dock, to Protalex or a designated site, as a single
                shipment. Each additional shipment will incur an additional $[*****]
                handling fee. 

            

    

    
      	 	
              ·

            	
              Complete
                the batch record and issue to
                Protalex.

            

    

    

    
      	
              Estimated
                Cost

            	
              $[*****]

            

    

    

    1Note:
      This quote does not include double blind labeling. The cost for double blind
      labeling will be covered in a separate service estimate. 

    

    
      
        
        

      

      
        Page
          6 of 12

        
          

        

      

      
        
        

      

    

    

    
      	 	
              IV.

            	
              Clinical
                Batch Stability 

            

    

    

    Stability
      evaluations will be performed on the drug product. Data reports will be provided
      as generated for each time point and a final report will be issued at the end
      of
      the study. A stability protocol will be developed by AAI and reviewed and
      accepted in writing by Protalex. 

    

    
      	
              TESTS
                PERFORMED

            
	
              1. Appearance

            
	
              2. pH

            
	
              3. Concentration
                by UV280 or mBCA

            
	
              4. Completeness,
                clarity and color of solution

            
	
              5. Moisture
                (cKF)

            
	
              6. PXI
                Binding Affinity (ELISA)

            
	
              7. SEC

            
	
              8. SDS-PAGE

            
	
              9. RP-HPLC

            
	
              10. Particulate
                matter (HIAC)

            
	
              11. Sterility
                (membrane filtration)

            

    

    

    SAMPLING
      SCHEDULE 

    
      	
              Time
                (Months)

            	
              25°C/60%
                RH

            	
              30°C/65%
                RH

            	
              40°C/75%
                RH

            
	
              0

            	
              Tests
                1-11

            
	
              1

            	
              Tests
                1-10

            	
              HOLD*

            	
              Tests
                1-10

            
	
              3

            	
              Tests
                1-10

            	
              HOLD*

            	
              Tests
                1-10

            
	
              6

            	
              Tests
                1-10

            	
              HOLD*

            	
              Tests
                1-10

            
	
              9

            	
              Tests
                1-10

            	
              HOLD*

            	
              N/A

            
	
              12

            	
              Tests
                1-11

            	
              HOLD*

            	
              N/A

            
	
              18

            	
              Tests
                1-10

            	
              N/A

            	
              N/A

            
	
              24

            	
              Tests
                1-11

            	
              N/A

            	
              N/A

            

    

    

    *HOLD
      samples will only be tested if significant change occurs during the 6 months
      storage at 40°C/75%
      RH,
      or if requested by Protalex, at an additional cost.

    

    
      	
              Estimated
                Cost

            	
              $[*****]

            

    

    

    
      
        
        

      

      
        Page
          7 of 12

        
          

        

      

      
        
        

      

    

    

    
      	 	
              V.

            	
              Project
                Management

            

    

    

    AAI
      will
      assign a Project Manager to communicate project progress, track projects, and
      facilitate project team meetings. Teleconferences will be held as needed between
      the project team and Protalex. The Project Manager will provide e-mail
      communications to Protalex updating the progress on any projects
      in-process.

    

    

    
      
        
        

      

      
        Page
          8 of 12

        
          

        

      

      
        
        

      

    

    

    Appendix
      II

    Payment
      Schedule and Terms

    

    The
      estimated cost for the activities outlined in this contract is $[*****].
      Materials and packaging components will be passed through to Client at cost
      plus
      15%. A summary of the breakdown costs is as follows: 

    

    
      	
              Service
                

              Agreement
                Section

            	
              Service
                Agreement Description

            	
              Estimated
                Cost

            
	
              Tasks
                I.

            	
              Project
                Responsibility

            	
              $[*****] 

            
	
              Task
                II.

            	
              Evaluation
                of Methods and Manufacture of Experimental Batch

            	
              $[*****]

            
	
              Task
                III.

            	
              Clinical
                Batch Manufacture 

            	
              $[*****]

            
	
              Task
                IV.

            	
              Clinical
                Batch Stability 

            	
              $[*****]

            
	
              TOTAL

            	 	
              $[*****]

            

    

    

    In
      addition, Client will be charged for all out-of-pocket costs and/or expenses
      associated with the activities outlined herein. Such costs and expenses shall
      include required raw materials, travel and shipping expenses, and lab supplies
      such as standards and chemicals unavailable from Client. All documented and
      reasonable out-of-pocket costs and/or expenses will be billed at cost plus
      15%.
      Actual costs based on vendor invoices plus 15% will be invoiced.

    

    This
      cost
      estimate is based on the information available and AAI’s experience with the
      procedures involved. AAI reserves the right to revise this Agreement should
      the
      scope of the project change. Any changes in the scope or the nature of the
      work
      covered by this service Agreement must be mutually agreed to and confirmed
      by a
      written change order.

    

    PAYMENT
      SCHEDULE

    
      	
              Payment

            	
               Payment
                Description

            	
              Amount

            
	
              1

            	
              Prepayment
                Due Upon Signature of Contract

            	
              [*****]

            
	
              2

            	
              Prototype
                Stability Initiation

            	
              [*****]

            
	
              3

            	
              Engineering
                Batch Initiation

            	
              [*****]

            
	
              4

            	
              Clinical
                Batch Initiation

            	
              [*****]

            
	
              5

            	
              Release
                of Clinical Batch by AAI to Protalex

            	
              [*****]

            
	
              6

            	
              Issue
                1 Month Stability Test Report

            	
              [*****]

            
	
              7

            	
              Issue
                3 Month Stability Test Report

            	
              [*****]

            
	
              8

            	
              Issue
                6 Month Stability Test Report

            	
              [*****]

            
	
              9

            	
              Issue
                9 Month Stability Test Report

            	
              [*****]

            
	
              10

            	
              Issue
                12 Month Stability Test Report

            	
              [*****]

            
	
              11

            	
              Issue
                18 Month Stability Test Report

            	
              [*****]

            
	
              12

            	
              Issue
                24 Month Stability Test Report

            	
              [*****]

            
	 	
              Total

            	
              $[*****]

            

    

    

    
      
        
        

      

      
        Page
          9 of 12

        
          

        

      

      
        
        

      

    

    Appendix
      III

    General
      Terms and Conditions

     

    
      a.
        Requirements Client
        will supply AAIPharma with this service estimate, or a copy of it, signed
        by the
        appropriate authorized Client representative. Client will also supply AAIPharma
        with a purchase order number and prepayment in the amount of
        $[*****].

       

      b.
        Invoicing Unless
        otherwise agreed, AAIPharma will invoice Client on a milestone basis. All
        invoices are due and payable upon receipt and are subject to 1.5% interest
        monthly after 30 days. In the event of default in the payment for services
        rendered, Client shall be responsible for all collection fees and expenses
        incurred by AAIPharma, including reasonable attorney’s fees.

       

      c.
        Good Manufacturing Practices AAIPharma
        operates its manufacturing facilities in compliance with applicable, current
        Good Manufacturing Practices and AAIPharma internal standard operating
        procedures, and is registered with the Food and Drug Administration,
        Registration Numbers 10-49418, 10-58430, 19-54450 and 10-55790 (Wilmington,
        NC;
        Research Triangle Park, NC; Shawnee, Kansas and Charleston, SC; respectively).
        

       

      d.
        Amendment
        No
        addition to or modification of this agreement shall be effective unless made
        in
        writing and signed by both parties, except the parties may orally agree to
        a
        change order (encompassing a change in project scope or definition) for
        additional services so long as the associated fee for such additional services
        does not exceed 10% of the relevant portion of the project cost. AAIPharma
        will
        confirm in writing any such oral change order, and Client will notify AAIPharma
        of any objections thereto within ten (10) days.

       

      e.
        Termination Client
        shall be entitled to terminate the project at any time on thirty (30) days'
        prior written notice. In the event of cancellation, Client will be obligated
        to
        pay only the cost of work, materials and services used for the project through
        the effective date of the cancellation and reasonable project shut down costs,
        as well as AAIPharma's cost of all materials and services previously acquired
        or
        contracted for and which cannot be utilized in other day-to-day operations.
        In
        the event the services described herein include clinical trials manufacturing,
        Client
        shall be
        entitled to terminate the project at any time on thirty (30) days written
        prior
        notice. If it does so, Client shall be obligated to pay the cost of all work
        completed through the effective date of termination in accordance with the
        foregoing and reasonable project shut down costs, as well as AAIPharma's
        cost of
        materials and services previously acquired, reserved or contracted which
        will
        not be used for this project as the result of such termination and which
        cannot
        be utilized in AAIPharma's other operations. In addition, a cancellation
        fee in
        the amount of $[*****]
        value
        shall be due AAIPharma should Client provide AAIPharma less than thirty (30)
        days and more than ten (10) days notice of cancellation in writing. Client
        shall
        pay AAIPharma a cancellation fee in the amount of $[*****]
        should
        it
        provide AAIPharma ten (10) days or less notice of cancellation in writing.
        Client shall not be charged a cancellation fee for any clinical supplies
        manufacturing orders canceled if a written notice of cancellation is received
        by
        AAIPharma more than thirty (30) days before the scheduled clinical supplies
        manufacturing.

       

      f.
        Cancellations and Rescheduling 

      •
All
        cancellation and rescheduling requests must be submitted in
        writing.

      •
        Cancellation or rescheduling of manufacturing runs within 0 to 30 days before
        the scheduled run will incur a fee of % of the Manufacturing Task Price.
        

      •
When
        canceling an entire project, the client forfeits the initial initiation fee
        paid
        at the beginning of the project and is responsible for project costs incurred
        up
        to the date of receipt of the cancellation notice as well as any associated
        costs to close down the project.

       

      g.
        Delivery Schedule Delivery
        dates, if any, in the proposal or in timelines are approximate only. AAIPharma
        shall not be liable for, nor shall AAIPharma be in breach of its obligations
        to
        client because of any delivery made within reasonable time of the stated
        delivery. AAIPharma may, by written notice to client, change any delivery
        date,
        and such date shall become the agreed upon delivery date unless client delivers
        to AAIPharma its objection to such date in writing within ten (10) days of
        receipt of AAIPharma’s notice.

    

     

    
      
        
        

      

      
        Page
          10 of
          12

        
          

        

      

      
        
        

      

    

     

    
      h.
        Safety
        information
        Client
        warrants that it will provide AAIPharma with all necessary safety information
        concerning chemical entities it supplies to AAIPharma, to ensure the safe
        handling, storage, usage, shipment and disposal of such chemical entities.
        Client is responsible for labeling and all other information relevant to
        the
        Product.

       

      i.
        Warranty
        AAIPharma warrants that all services performed by it hereunder conform to
        the
        requirements of the Service Agreement (the “Services”). The foregoing warranty
        is made to Client only and is not transferable. AAIPHARMA MAKES NO WARRANTIES,
        EITHER EXPRESS, IMPLIED OR OTHERWISE, EXCEPT THOSE HEREIN EXPRESSLY PROVIDED.
        AAIPHARMA SPECIFICALLY DISCLAIMS THE IMPLIED WARRANTIES OF MERCHANTABILITY,
        FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NON-INFRINGEMENT AND ANY WARRANTY,
        EXPRESS OR IMPLIED, THAT THE ACTUAL SCIENTIFIC OR PHARMACEUTICAL RESULTS
        OF THE
        SERVICES HEREUNDER WILL NECESSARILY MEET CLIENT’S DESIRED SCIENTIFIC OR
        PHARMACEUTICAL RESULTS.

       

      j.
        Liability Limitation
        AAIPharma will perform all services according to good scientific practices
        and
        in conformity with relevant cGMP's; however, both parties recognize that
        as
        specified herein services constitute research and development efforts.
        Therefore, the parties agree that AAIPharma's entire liability for performing
        these services is limited to the amount of compensation received from Client
        pursuant to this Service Estimate. Notwithstanding anything in this Service
        Estimate or otherwise to the contrary, in no event shall AAIPharma or its
        affiliates be liable under any theory, including negligence, for lost profits,
        or special, incidental, consequential, indirect, punitive or exemplary damages.
        

       

      k.
        Indemnification Client
        shall defend, indemnify and hold harmless AAIPharma, its directors, officers,
        employees, agents and representatives from any claims, proceedings or
        investigations arising out of or in connection with the Services, including,
        without limitation, amounts paid in settlement of claims, proceedings or
        investigations, and shall bear all expenses, fees or costs in connection
        therewith (“Loss”), provided that such Loss is not the result of AAIPharma’s
        gross negligence or willful misconduct. 

       

      l.
        Proprietary Information and Technology Client
        will own all data and written reports arising out of this project and all
        chemical entities supplied by Client or prepared for Client in this project
        upon
        payment for Services. Any patent or other intellectual property rights directly
        resulting from information supplied by Client to AAIPharma in the performance
        of
        this project will be assigned to Client. Notwithstanding the foregoing,
        AAIPharma shall retain ownership of any inventions, processes, techniques,
        improvements, know-how, trade secrets, discoveries and other intellectual
        properties and other assets which have been, or will be, developed by AAIPharma
        independent of the Services and this Service Estimate (hereinafter, “AAIPharma
        Proprietary Technology”). In the event Client chooses to further develop and/or
        commercialize a technology comprising, in whole or in part, AAIPharma
        Proprietary Technology, Client must first obtain a license from AAIPharma
        to use
        such AAIPharma Proprietary Technology. Such license agreement shall be
        memorialized in a separate writing containing mutually agreeable terms
        negotiated in good faith by AAIPharma and Client. Client agrees to indemnify
        AAIPharma against any liability for infringement of any patent or other
        intellectual property rights arising from Client-directed services or
        Client-supplied information in the performance of this project. 

       

      m.
        Nondisclosure AAIPharma
        agrees, for a period of five (5) years from the date hereof, that, except
        to the
        extent required by law, regulation, judicial requirement, or regulatory agency,
        it will not itself use, or provide or disclose to any third party, or permit
        any
        third party to use, any information, data, or documents which were specifically
        developed or generated by AAIPharma for Client other than any AAIPharma
        Proprietary Technology incorporated therein.

       

      n.
        Excluded Materials Notwithstanding
        the nondisclosure section set forth above, information, data, or documents
        developed or generated by AAIPharma for its internal use or for third parties
        other than Client is not restricted by the ownership rights to be transferred
        to
        Client herein. Further, data and technology relating to the synthesis of
        raw
        material and dosage forms other than Client’s product is not restricted by this
        Agreement for AAIPharma's subsequent use.

      
        
          
          

        

        
          Page
            11 of
            12

          
            

          

        

        
          
          

        

      

      o.
        Choice of Law This
        Service Estimate shall be interpreted and construed in accordance with the
        laws
        of the State of Delaware, without the application of its choice of law
        provisions to the contrary.

       

      p.
        Force Majeure
        AAIPharma shall not be liable for any failure to meet its obligations under
        this
        Agreement due to any cause beyond AAIPharma’s reasonable control, including,
        without limitation, acts of public enemy, acts of any governmental authority,
        including governmental laws, ordinances, rules and regulations whether or
        not
        valid, acts of God, including hurricanes, floods, epidemics and unusually
        severe
        weather, quarantine restrictions, strikes or lockouts, labor disputes or
        shortages, embargoes, war, riot, malicious acts or damage, accidents,
        interruption of supplies, equipment malfunction or failure of electrical
        supply
        or other utilities.

       

      q.
        Inspection Both
        parties recognize that proper authorities may request that AAIPharma produce
        records, data, or materials related to Client products during the course
        of, or
        as the subject of, an inspection. In such instances, AAIPharma will notify
        AAIPharma’s contact at Client of such regulatory inspection.

       

      r.
        Survival Paragraphs
        g, h, i, j, k, l, m, p and q of this Appendix III shall survive the expiration,
        cancellation or termination of this Service Agreement.

       

      s.
        Samples Any
        and
        all materials received and associated with this Service Estimate will be
        treated
        as laboratory testing samples only, not for use in humans. After the final
        stability time point, by completion or cancellation of the stability study,
        AAIPharma will retain any sample overage in the controlled stability storage
        environment for a period of 2 months. After that time the samples will
        automatically be returned to Client or destroyed by appropriate means in
        Wilmington, NC. Please initial and date one selection:

       

      Client
        would like for AAIPharma to ______return_____ destroy the remaining
        samples.

       

      If
        the
        disposition of the samples is not indicated, the samples will be returned
        to
        Client at the end of the 2-month retain period. All shipping charges will
        be
        Client’s responsibility.

    

     

    
      
        
        

      

      
        Page
          12 of
          12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}]]